M L Selley

Summary

Affiliation: Angiogen Pharmaceuticals Pty. Ltd
Country: Australia

Publications

  1. ncbi request reprint Homocysteine increases the production of asymmetric dimethylarginine in cultured neurons
    Michael L Selley
    Angiogen Pharmaceuticals Pty Ltd, Sydney, New South Wales, Australia
    J Neurosci Res 77:90-3. 2004
  2. ncbi request reprint Increased concentrations of homocysteine and asymmetric dimethylarginine and decreased concentrations of nitric oxide in the plasma of patients with Alzheimer's disease
    M L Selley
    Angiogen Pharmaceuticals Pty Ltd, P O Box 512, Turramurra, NSW 2074, Australia
    Neurobiol Aging 24:903-7. 2003
  3. ncbi request reprint The effect of increased concentrations of homocysteine on the concentration of (E)-4-hydroxy-2-nonenal in the plasma and cerebrospinal fluid of patients with Alzheimer's disease
    M L Selley
    Angiogen Pharmaceuticals Pty Ltd, Turramurra, New South Wales 2074, Australia
    Neurobiol Aging 23:383-8. 2002
  4. ncbi request reprint Increased (E)-4-hydroxy-2-nonenal and asymmetric dimethylarginine concentrations and decreased nitric oxide concentrations in the plasma of patients with major depression
    Michael L Selley
    Angiogen Pharmaceuticals Pty Ltd, P O Box 512, Turramurra, N S W 2074, Australia
    J Affect Disord 80:249-56. 2004
  5. ncbi request reprint Increased homocysteine and decreased adenosine formation in Alzheimer's disease
    Michael L Selley
    Angiogen Pharmaceuticals Pty Ltd, Sydney, N S W, Australia
    Neurol Res 26:554-7. 2004
  6. ncbi request reprint Simvastatin prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice
    Michael L Selley
    Angiogen Pharmaceuticals Pty Ltd, Level 31, ABN AMRO Tower, 88 Phillip Street, Sydney, N S W 2000, Australia
    Brain Res 1037:1-6. 2005
  7. ncbi request reprint A metabolic link between S-adenosylhomocysteine and polyunsaturated fatty acid metabolism in Alzheimer's disease
    Michael L Selley
    Angiogen Pharmaceuticals Pty Ltd, Level 31, ABN AMRO Tower, 88 Phillip Street, Sydney, NSW 2000, Australia
    Neurobiol Aging 28:1834-9. 2007
  8. ncbi request reprint Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite
    Michael Platten
    Department of Neurology and Neurological Sciences, Beckman Center for Molecular Medicine, Stanford University, Stanford, CA 94305, USA
    Science 310:850-5. 2005

Collaborators

Detail Information

Publications8

  1. ncbi request reprint Homocysteine increases the production of asymmetric dimethylarginine in cultured neurons
    Michael L Selley
    Angiogen Pharmaceuticals Pty Ltd, Sydney, New South Wales, Australia
    J Neurosci Res 77:90-3. 2004
    ..The preservation of DDAH activity and the reduction of ADMA accumulation in neurons may be a new strategy for the treatment of Alzheimer's disease and cognitive impairment in normal aging...
  2. ncbi request reprint Increased concentrations of homocysteine and asymmetric dimethylarginine and decreased concentrations of nitric oxide in the plasma of patients with Alzheimer's disease
    M L Selley
    Angiogen Pharmaceuticals Pty Ltd, P O Box 512, Turramurra, NSW 2074, Australia
    Neurobiol Aging 24:903-7. 2003
    ..The inhibition of neuronal nitric oxide synthesis by ADMA may cause cognitive dysfunction in Alzheimer's disease...
  3. ncbi request reprint The effect of increased concentrations of homocysteine on the concentration of (E)-4-hydroxy-2-nonenal in the plasma and cerebrospinal fluid of patients with Alzheimer's disease
    M L Selley
    Angiogen Pharmaceuticals Pty Ltd, Turramurra, New South Wales 2074, Australia
    Neurobiol Aging 23:383-8. 2002
    ..850, P = 0.007) and HNE (r = 0.092, P = 0.002). These results demonstrate that there is a relationship between increased homocysteine concentrations and increased HNE concentrations in Alzheimer's disease...
  4. ncbi request reprint Increased (E)-4-hydroxy-2-nonenal and asymmetric dimethylarginine concentrations and decreased nitric oxide concentrations in the plasma of patients with major depression
    Michael L Selley
    Angiogen Pharmaceuticals Pty Ltd, P O Box 512, Turramurra, N S W 2074, Australia
    J Affect Disord 80:249-56. 2004
    ..Major depression is associated with the development of coronary heart disease (CHD) and greatly increases morbidity and mortality. There is an increase in circulating ADMA in CHD and vascular risk factors...
  5. ncbi request reprint Increased homocysteine and decreased adenosine formation in Alzheimer's disease
    Michael L Selley
    Angiogen Pharmaceuticals Pty Ltd, Sydney, N S W, Australia
    Neurol Res 26:554-7. 2004
    ..773, p < 0.0001). The decrease in adenosine formation may play a role in the vascular pathology of homocysteine in Alzheimer's disease...
  6. ncbi request reprint Simvastatin prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice
    Michael L Selley
    Angiogen Pharmaceuticals Pty Ltd, Level 31, ABN AMRO Tower, 88 Phillip Street, Sydney, N S W 2000, Australia
    Brain Res 1037:1-6. 2005
    ..Simvastatin may be a potential new treatment to slow the progression of Parkinson's disease...
  7. ncbi request reprint A metabolic link between S-adenosylhomocysteine and polyunsaturated fatty acid metabolism in Alzheimer's disease
    Michael L Selley
    Angiogen Pharmaceuticals Pty Ltd, Level 31, ABN AMRO Tower, 88 Phillip Street, Sydney, NSW 2000, Australia
    Neurobiol Aging 28:1834-9. 2007
    ..The evidence suggests that a metabolic link between the increased production of SAH and phospholipid metabolism may contribute to cerebrovascular and neurodegenerative changes in Alzheimer's disease...
  8. ncbi request reprint Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite
    Michael Platten
    Department of Neurology and Neurological Sciences, Beckman Center for Molecular Medicine, Stanford University, Stanford, CA 94305, USA
    Science 310:850-5. 2005
    ..Trp catabolites and their derivatives offer a new strategy for treating T(H)1-mediated autoimmune diseases such as MS...